Acute effects of moderate altitude on biomarkers of cardiovascular inflammation and endothelial function and their differential modulation by dual endothelin receptor blockade
Restricted accessResearch articleFirst published online October 12, 2017
Acute effects of moderate altitude on biomarkers of cardiovascular inflammation and endothelial function and their differential modulation by dual endothelin receptor blockade
Endothelial dysfunction is accompanied by the release of microparticles (MP).
OBJECTIVE:
We sought to investigate the effect of moderate hypoxia on circulatory levels of microparticles, biomarkers of cardiovascular function and inflammation and on echocardiographic parameters in healthy volunteers staying at an altitude of 2978 m.
METHODS:
Eighteen healthy volunteers were subjected to moderate hypoxia by staying at 2978 m above sea level for three days. Blood samples were evaluated for MP using flow cytometry. ELISA analysis was performed for sST2, H-FABP, suPAR and GDF-15. Moreover, the effect of dual endothelin-receptor blockade was investigated.
RESULTS:
Oxygen saturation decreased to 93%. A significant decrease of endothelial and platelet MP levels was found. These results were corroborated by a similar response in sST2 and suPAR plasma concentration. Endothelin-receptor blockade by macitentan only had a marginal influence on MP, sST2, H-FABP, suPAR and GDF-15 levels, though it led to a significant amelioration of echocardiographic parameters of right heart function.
CONCLUSIONS:
These experimental results show that moderate hypoxia due to altitude exposition led to a reduction in parameters of endothelial dysfunction as shown by a decrease in endothelial and platelet MP, sST2 and suPAR levels. A slight increase in pulmonary pressure at moderate altitude was decreased by dual endothelin receptor blockade.
ThomasD. and GiuglianoR.P., Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe, Am Heart J158 (2009), 695–705. doi: 10.1016/j.ahj.2009.08.023
2.
VelagaletiR.S., PencinaM.J., MurabitoJ.M., et al., Long-term trends in the incidence of heart failure after myocardial infarction, Circulation118 (2008), 2057–2062. doi: 10.1161/CIRCULATIONAHA.108.784215
3.
JungC., RafnssonA., ShemyakinA., et al., Different subpopulations of endothelial progenitor cells and circulating apoptotic progenitor cells in patients with vascular disease and diabetes, Int J Cardiol143 (2010), 368–372. doi: 10.1016/j.ijcard.2009.03.075
4.
MudauM., GenisA., LochnerA. and StrijdomH., Endothelial dysfunction: The early predictor of atherosclerosis, Cardiovasc J Afr23 (2012), 222–231. doi: 10.5830/CVJA-2011-068
5.
HeuschG., LibbyP., GershB., et al., Cardiovascular remodelling in coronary artery disease and heart failure, Lancet Lond Engl383 (2014), 1933–1943. doi: 10.1016/S0140-6736(14)60107-0
6.
BaronM., BoulangerC.M., StaelsB. and TailleuxA., Cell-derived microparticles in atherosclerosis: Biomarkers and targets for pharmacological modulation?J Cell Mol Med16 (2012), 1365–1376. doi: 10.1111/j.1582-4934.2011.01486.x
7.
JungC., DrummerK., OelznerP., et al., The association between endothelial microparticles and inflammation in patients with systemic sclerosis and Raynaud’s phenomenon as detected by functional imaging, Clin Hemorheol Microcirc61 (2015), 549–557. doi: 10.3233/CH-151956
8.
MarkiewiczM., RichardE., MarksN. and Ludwicka-BradleyA., Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases, J Aging Res2013 (2013), 734509. doi: 10.1155/2013/734509
9.
Bernal-MizrachiL., JyW., JimenezJ.J., et al., High levels of circulating endothelial microparticles in patients with acute coronary syndromes, Am Heart J145 (2003), 962–970. doi: 10.1016/S0002-8703(03)00103-0
10.
MichelsenA.E., BrodinE., BrosstadF. and HansenJ.-B., Increased level of platelet microparticles in survivors of myocardial infarction, Scand J Clin Lab Invest68 (2008), 386–392. doi: 10.1080/00365510701794957
11.
ZielińskaM., KoniarekW., GochJ.H., et al., Circulating endothelial microparticles in patients with acute myocardial infarction, Kardiol Pol62 (2005), 531-542-544.
12.
LiuY., HeZ., ZhangY., et al., Dissimilarity of increased phosphatidylserine-positive microparticles and associated coagulation activation in acute coronary syndromes, Coron Artery Dis27 (2016), 365–375. doi: 10.1097/MCA.0000000000000368
13.
VinceR.V., ChrismasB., MidgleyA.W., et al., Hypoxia mediated release of endothelial microparticles and increased association of S100A12 with circulating neutrophils, Oxid Med Cell Longev2 (2009), 2–6.
14.
WangJ., ChenS., MaX., et al., Effects of endothelial progenitor cell-derived microvesicles on hypoxia/reoxygenation-induced endothelial dysfunction and apoptosis, Oxid Med Cell Longev2013 (2013), 572729. doi: 10.1155/2013/572729
15.
LichtenauerM., GoebelB., FritzenwangerM., et al., Simulated temporary hypoxia triggers the release of CD31+/Annexin+ endothelial microparticles: A prospective pilot study in humans, Clin Hemorheol Microcirc61 (2015), 83–90. doi: 10.3233/CH-141908
16.
RohmI., RatkaJ., PistulliR., et al., Impact of systemic normobaric short-term hypoxia on pro-inflammatory and anti-inflammatory cytokines in healthy volunteers, Clin Lab61 (2015), 1053–1059.
17.
YilmazA., RatkaJ., RohmI., et al., Decrease in circulating plasmacytoid dendritic cells during short-term systemic normobaric hypoxia, Eur J Clin Invest46 (2016), 115–122. doi: 10.1111/eci.12416
18.
LichtenauerM., ZimmermannM., NicklS., et al., Transient hypoxia leads to increased serum levels of heat shock protein-27, -70 and caspase-cleaved cytokeratin 18, Clin Lab60 (2014), 323–328.
19.
AyersL., StoewhasA.-C., FerryB., et al., Circulating levels of cell-derived microparticles are reduced by mild hypobaric hypoxia: Data from a randomised controlled trial, Eur J Appl Physiol114 (2014), 1067–1073. doi: 10.1007/s00421-014-2837-6
20.
TominagaS., A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor, FEBS Lett258 (1989), 301–304.
21.
WerenskioldA.K., HoffmannS. and KlemenzR., Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts, Mol Cell Biol9 (1989), 5207–5214.
22.
SchmitzJ., OwyangA., OldhamE., et al., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines, Immunity23 (2005), 479–490. doi: 10.1016/j.immuni.2005.09.015
23.
ShimpoM., MorrowD.A., WeinbergE.O., et al., Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction, Circulation109 (2004), 2186–2190. doi: 10.1161/01.CIR.0000127958.21003.5A
BhardwajA. and JanuzziJ.L., ST2: A novel biomarker for heart failure, Expert Rev Mol Diagn10 (2010), 459–464. doi: 10.1586/erm.10.25
26.
BrochK., AndreassenA.K., UelandT., et al., Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure, Int J Cardiol179 (2015), 378–384. doi: 10.1016/j.ijcard.2014.11.003
27.
NiizekiT., TakeishiY., ArimotoT., et al., Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure, Circ J Off J Jpn Circ Soc72 (2008), 109–114.
28.
BoscheriA., WunderlichC., LangerM., et al., Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk, Am Heart J160 (2010), 294–300. doi: doi: 10.1016/j.ahj.2010.05.010
29.
HuaiQ., MazarA.P., KuoA., et al., Structure of human urokinase plasminogen activator in complex with its receptor, Science311 (2006), 656–659. doi: 10.1126/science.1121143
30.
ThunøM., MachoB. and Eugen-OlsenJ., suPAR: The molecular crystal ball, Dis Markers27 (2009), 157–172. doi: 10.3233/DMA-2009-0657
31.
FazioliF., ResnatiM., SideniusN., et al., A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity, EMBO J16 (1997), 7279–7286. doi: 10.1093/emboj/16.24.7279
32.
WittenhagenP., KronborgG., WeisN., et al., The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality, Clin Microbiol Infect10 (2004), 409–415. doi: 10.1111/j.1469-0691.2004.00850.x
33.
FernebroE., MadsenR.R., FernöM., et al., Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients, Eur J Cancer Oxf Engl 199037 (2001), 486–491.
34.
Eugen-OlsenJ., AndersenO., LinnebergA., et al., Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population, J Intern Med268 (2010), 296–308. doi: 10.1111/j.1365-2796.2010.02252.x
35.
BootcovM.R., BauskinA.R., ValenzuelaS.M., et al., MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily, Proc Natl Acad Sci U S A94 (1997), 11514–11519.
36.
WollertK.C. and KempfT., Growth differentiation factor 15 in heart failure: An update, Curr Heart Fail Rep9 (2012), 337–345. doi: 10.1007/s11897-012-0113-9
37.
SuA.I., WiltshireT., BatalovS., et al., A gene atlas of the mouse and human protein-encoding transcriptomes, Proc Natl Acad Sci U S A101 (2004), 6062–6067. doi: 10.1073/pnas.0400782101
38.
LindahlB., The story of growth differentiation factor 15: Another piece of the puzzle, Clin Chem59 (2013), 1550–1552. doi: 10.1373/clinchem.2013.212811
39.
CombesV., SimonA.-C., GrauG.-E., et al., In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant, J Clin Invest104 (1999), 93–102.
40.
JungC., SörenssonP., SalehN., et al., Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction, Atherosclerosis221 (2012), 226–231. doi: 10.1016/j.atherosclerosis.2011.12.025
41.
PirroM., SchillaciG., PaltricciaR., et al., Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia, Arterioscler Thromb Vasc Biol26 (2006), 2530–2535. doi: 10.1161/01.ATV.0000243941.72375.15
42.
GarveyJ.F., TaylorC.T. and McNicholasW.T., Cardiovascular disease in obstructive sleep apnoea syndrome: The role of intermittent hypoxia and inflammation, Eur Respir J33 (2009), 1195–1205. doi: 10.1183/09031936.00111208
43.
SchulzR., MahmoudiS., HattarK., et al., Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy, Am J Respir Crit Care Med162 (2000), 566–570. doi: 10.1164/ajrccm.162.2.9908091
44.
MilletG.P., RoelsB., SchmittL., et al., Combining hypoxic methods for peak performance, Sports Med Auckl NZ40 (2010), 1–25. doi: 10.2165/11317920-000000000-00000
45.
MoncayoJ., de FreitasG.R., BogousslavskyJ., et al., Do transient ischemic attacks have a neuroprotective effect?Neurology54 (2000), 2089–2094.
46.
WeihM., KallenbergK., BergkA., et al., Attenuated stroke severity after prodromal TIA: A role for ischemic tolerance in the brain?Stroke30 (1999), 1851–1854.
47.
MoonH.-W., ShinS.-H., LeeC.-H., et al., Effects of various acute hypoxic conditions on the hemorheological response during exercise and recovery1, Clin Hemorheol Microcirc63 (2016), 451–460. doi: 10.3233/CH-16163
48.
Bayes-GenisA., ZhangY. and KyB., ST2 and patient prognosis in chronic heart failure, Am J Cardiol115 (2015), 64B–69B. doi: 10.1016/j.amjcard.2015.01.043
49.
RichardsA.M., Di SommaS. and MuellerT., ST2 in stable and unstable ischemic heart diseases, Am J Cardiol115 (2015), 48B–58B. doi: 10.1016/j.amjcard.2015.01.041
50.
TambaraK., FujitaM., MiyamotoS., et al., Pericardial fluid level of heart-type cytoplasmic fatty acid-binding protein (H-FABP) is an indicator of severe myocardial ischemia, Int J Cardiol93 (2004), 281–284. doi: 10.1016/S0167-5273(03)00219-5
51.
TognoliE., Luigi Giuseppe LeoniM., MorelliD., et al., Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication, Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc24 (2016), 1036–1040. doi: 10.1111/wrr.12493
52.
EzzatiM., HorwitzM.E.M., ThomasD.S.K., et al., Altitude, life expectancy and mortality from ischaemic heart disease, stroke, COPD and cancers: National population-based analysis of US counties, J Epidemiol Community Health66 (2012), e17. doi: 10.1136/jech.2010.112938
53.
MortimerE.A., MonsonR.R. and MacMahonB., Reduction in mortality from coronary heart disease in men residing at high altitude, N Engl J Med296 (1977), 581–585. doi: 10.1056/NEJM197703172961101
